

11:00–12:30 | Tallinn - Village 7

CARDIAC PACING 2012 AND BEYOND

Symposium

Chairperson(s): R. Hatala (Bratislava, SK); G. Milasinovic (Belgrade, RS)

- 11:00 **Current pacing and sensing algorithms. The clinical value and the cost of follow-up.** 2275
– M. Brignole (Lavagna, IT)
- 11:22 **Is remote follow-up of cardiac pacing the future?** 2276
– P. Mabo (Rennes, FR)
- 11:45 **Diagnostic capabilities of the implantable therapeutic systems.** 2277
– P. Raatikainen (Tampere, FI)
- 12:07 **Leadless pacing: technical challenges and concerns.** 2278
– P.E. Vardas (Heraklion, GR)

11:00–12:30 | Tel Aviv - Village 7

NEW APPROACHES TO ANTIARRHYTHMIC DRUG THERAPY

Abstract Session

Chairperson(s): J.L. Tamargo (Madrid, ES); S. Dhein (Leipzig, DE)

- 11:00 **Ranolazine amplifies the antiarrhythmic effect of amiodarone and dronedarone in an experimental whole-heart model of atrial fibrillation.** 2279
– G. Frommeyer, S. Kaese, T. Uphaus, C. Pott, L. Eckardt, P. Millberg (Münster, DE)
- 11:15 **Cathepsin A -inhibition reduces susceptibility to atrial tachyarrhythmia and prevents impairment of atrial emptying function in old Zucker diabetic fatty rats.** 2280
– D. Linz, S. Dhein, H.P. Juretschke, C. Neumann-Haefelin, S. Ruf, P. Wohlfahrt, T. Sadowski, H. Ruetten, M. Böhm, U. Schotten (Homburg, Leipzig and Frankfurt/Main, DE; Maastricht, NL)
- 11:30 **Aliskiren, a direct renin inhibitor, suppresses the atrial structural remodeling and fibrotic gene expressions in the canine atrial fibrillation model.** 2281
– A. Satoh, S. Niwano, H. Niwano, J. Oikawa, J. Kishihara, Y. Aoyama, S. Ishikawa, M. Murakami, Y. Yumoto, T. Izumi (Sagamihara, JP)
- 11:45 **Reversed transmural activation-repolarisation gradient in Brugada syndrome exacerbated by increased cholinergic tone.** 2282
– J. Bhar-Amato, S. Chaubey, X. Jie, M. Finlay, L. Xu, L. Nunn, O. Segal, M. Lowe, E. Rowland, P. Lambiase (London, GB)
- 12:00 **Long-term outcomes in a case series of patients diagnosed of inappropriate sinus tachycardia treated with ivabradine.** 2283
– J. Benezet Mazuecos, J.M. Rubio, M.A. Quinones, H.P. Gaebel, E. Macia, S. Del Castillo, J. Farre (Madrid, ES)
- 12:15 **Mean duration of AF episodes in the PASCAL (Paroxysmal Atrial fibrillation Study with Continuous Atrial fibrillation Logging) study are reduced by treatment with higher doses of budiodarone.** 2284
– P.G. Milner, D.J. Ellis, D. Canafax, M. Ziola, M.D. Ezekowitz, S.H. Hohnloser (Palo Alto, Cupertino, South San Francisco, Fremont and Wynnewood, US; Frankfurt, DE)

11:00–12:30 | Helsinki - Village 8

HEART FAILURE IN ADULT CONGENITAL HEART DISEASE

Symposium

Chairperson(s): G.D. Webb (Cincinnati, US); P. Trigo Trindade (Basel, CH)

- 11:00 **The failing systemic right ventricle.** 2285
– A. Redington (Toronto, CA)
- 11:22 **The role of biomarkers.** 2286
– C. Mueller (Basel, CH)
- 11:45 **What is different about drug treatment?** 2287
– G.P. Diller (London, GB)
- 12:07 **Suitability for and results of transplantation.** 2288
– M. Chaudhari (Newcastle-upon-Tyne, GB)

11:00–12:30 | Rome - Village 8

CARDIOMYOPATHIES IN EUROPE AND AMERICAS

Symposium

ESC and the Interamerican Society of Cardiology

Chairperson(s): S.B. Felix (Greifswald, DE); D.J. Pineiro (Buenos Aires, AR)

- 11:00 **Inflammatory cardiomyopathies.** 2289
– H.P. Schultheiss (Berlin, DE)
- 11:22 **Peripartum cardiomyopathies.** 2290
– K. Sliwa-Hahnle (Cape Town, ZA)
- 11:45 **Chagasic cardiomyopathy.** 2291
– A.L. Ribeiro (Belo Horizonte, BR)
- 12:07 **Endomyocardial fibrosis.** 2292
– R. Migliore (San Martin, AR)

14:45–16:15 | Nicosia - Village 3

ASSESSING AND MANAGING ON-TREATMENT CARDIOVASCULAR RISK: WHEN KEY “QUANTITY” TARGETS ARE MET, IN WHICH PATIENTS DOES “QUALITY” MAKE THE DIFFERENCE? PITAVASTATIN – A NEW TREATMENT OPTION IN PATIENTS WITH HIGH CARDIOVASCULAR RISK

Satellite Symposium

Sponsored by Recordati S.p.A / Kowa

Chairperson(s): K.K. Ray (London, GB); J. Chapman (Paris, FR)

- 14:45 **Chair’s introduction.** 4643
– K.K. Ray (London, GB)
- 14:50 **Persistent challenges in the management of dyslipidaemia.** 4644
– J. Chapman (Paris, FR)
- 15:00 **Pitavastatin in high risk patients: adding “quality” to “quantity”.** 4645
– T. Hiro (Ube, JP)
- 15:25 **Pitavastatin: a new tool to address persistent challenges.** 4646
– J.R. Gonzalez Juanatey (Santiago de Compostela, ES), P. Marques da Silva (Lisbon, PT)
- 15:55 **Audience Q&A.** 4647
– K.K. Ray (London, GB)
- 16:10 **Chairs wrap up and close.** 4648
– J. Chapman (Paris, FR)

14:45–16:15 | Vienna - Village 4

THE STEPS OF STABLE ISCHEMIC HEART DISEASE PATIENT’S MANAGEMENT

Satellite Symposium

Sponsored by The Menarini Group

Chairperson(s): C.W. Hamm (Bad Nauheim, DE); J.L. Lopez-Sendon (Madrid, ES)

- 14:45 **Welcome & introduction.** 4649
– C.W. Hamm (Bad Nauheim, DE)
- 14:50 **The 1st step; to identify the stable ischemic heart disease patient.** 4650
– C. Daly (Dublin, IE)
- 15:15 **The 2nd step: to reach the hub of the stable ischemic heart disease.** 4651
– J.L. Tamargo (Madrid, ES)
- 15:40 **The 3rd step: the successful management for the identified ischemic patients.** 4652
– P.A. Merlini (San Donato Milanese, IT)
- 16:05 **Conclusions & summary.** 4653
– J.L. Lopez-Sendon (Madrid, ES)

15:30–16:30 | Moderated Posters - Village 10

SECONDARY PREVENTION: FROM AWARENESS TO ACTION

Moderated Posters

Chairperson(s): L. Ryden (Stockholm, SE); H. Voeller (Rudersdorf, DE)

Posters must be set up between 13:30 and 14:00, removed between 18:00 and 18:30 and be on display from 14:00 to 18:00. The following abstracts were chosen for their outstanding quality and will be discussed in a special area in the Poster hall during the Moderated Poster Session chaired by the two above-mentioned chairpersons between 15:30 and 16:30.

- 15:30 **Prevalence, co-prevalence and awareness of cardiovascular risk factors - results from the population based Gutenberg Health Study.** P4654
– J. Prochaska, S. Goebel, A. Schulz, R.B. Schnabel, N. Khuseynova, S. Herkenhoff, C. Espinola-Klein, S. Blankenberg, T. Muenzel, P.S. Wild (Mainz and Hamburg, DE)
- 15:37 **Use of lipid lowering therapy in primary care across Europe: results from the European study on cardiovascular risk prevention in daily practice (eurika).** P4655
– J.P.J. Halcox, F. Tubach, J.R. Banegas, C. Borghi, J. Dallongeville, G. De Backer, J. Perk, P.G. Steg, F. Rodriguez-Artalejo, E. Guallar (Cardiff, GB; Paris and Lille, FR; Madrid, ES; Bologna, IT; Ghent, BE; Kalmar, SE)
- 15:45 **Low levels of IgM antibodies against phosphorylcholine (anti-PC) increase the risk of ischemic cardiovascular events among European men at high risk of cardiovascular events.** P4656
– B. Gigante, K. Leander, R. Strawbridge, B. Sennblad, F. Veglia, D. Baldassarre, E. Tremoli, S.E. Humphries, J. Frostegard, U. De Faire (Stockholm, SE; Milan, IT; London, GB)
- 15:52 **Fasting and postprandial triglycerides are independent cardiovascular risk markers in non-obese coronary artery disease patients with normal glucose tolerance.** P4657
– C. Werner, S. Groenewold, M. Fritsch, A. Filmer, S. Graeber, M. Böhm, U. Laufs (Homburg, DE)
- 16:00 **The effect of plant stanol esters on blood flow in adults.** P4658
– P. Simonen, H. Gylling, H. Lindholm, J. Konttinen, M.J. Nissinen, M. Hallikainen (Helsinki and Kuopio, FI)
- 16:07 **Reduced blood pressure and risk of future cardiovascular disease from structured care algorithm in primary care patients with persistent hypertension: a multicentre randomized controlled trial.** P4659
– S. Stewart, M.J. Carrington, C.H. Swemmer, N.P. Kurstjens, G.J. Jennings (Melbourne and Sydney, AU)
- 16:15 **Successful weight loss following gastric sleeve surgery improves vascular function in obese individuals.** P4660
– M.E. Iancu, C.A. Copaescu, C. Ginghina (Bucharest, RO)
- 16:22 **The ferrari corporate wellness program: a new concept of cardiovascular prevention in the companies.** P4661
– F. Fernando, A. Biffi, A. Carluccio, M.T. Carluccio, A.F.G. Cicero, C. Borghi (Rome and Bologna, IT)

08:30–10:00 | Beirut - Village 1



BENCH TO PRACTICE: CLUES FROM THE GENES

Abstract Session

Chairperson(s): S. Kaab (Munich, DE); J. Hall (Minneapolis, US)

- 08:30 **A blood pressure genetic risk score predicts incident cardiovascular events in 36,950 Finnish individuals.** 5184
 – V. Salomaa, A.S. Havulinna, J. Kettunen, J. Eriksson, A. Jula, K. Kontula, C. Newton-Cheh (Helsinki and Turku, FI; Boston, US)
- 08:45 **A variant in the ABO gene explains the variation in soluble E-selectin levels - results from dense-genotyping in two independent populations.** 5185
 – M. Karakas, J. Baumert, M.E. Kleber, B. Thorand, D. Dallmeier, W. Rottbauer, C. Meisinger, T. Illig, W. Maerz, W. Koenig (Ulm, Neuherberg and Mannheim, DE)
- 09:00 **Gene-gene interactions in coronary artery disease.** 5186
 – M.D. Musameh, W.Y.S. Wang, C.P. Nelson, A.J. Balmforth, S.G. Ball, A.S. Hall, M. Tomaszewski, N.J. Samani (Leicester and Leeds, GB; Brisbane, AU)
- 09:15 **A genetic variant near adrenomedullin gene is associated with arterial rigidity.** 5187
 – F. Beygui, P.S. Wild, T. Zeller, V. Truong, T. Munzel, G. Montalescot, D.A. Tregouet, F. Cambien, S. Blankenberg, L. Tiret (Paris, FR; Mainz and Hamburg, DE)
- 09:30 **Functional effects of p.D1690N and p.G1748D Nav1.5 mutations detected in compound heterozygosity in a patient with Brugada syndrome.** 5188
 – R. Caballero, L. Nunez, A. Barana, P. Dolz-Gaiton, M. Gonzalez De La Fuente, I. Amoros, L. Monserrat, E. Delpon, A. Castro-Beiras, J. Tamargo (Madrid and Corunna, ES)
- 09:45 **Genome wide association study identifies the kallikrein-kinin system to regulate plasma levels of mid-regional-proadrenomedullin and C-Terminal-proendothelin-1.** 5189
 – N. Verweij, H. Mahmud, I. Mateo Leach, F.P. Brouwers, F.W. Asselbergs, R. De Boer, H.L. Hillege, W.H. Van Gilst, H.M.W. Sillje, P. Van Der Harst (Groningen and Utrecht, NL)

08:30–10:00 | Riga - Village 1



FROM BENCH TO PRACTICE: MECHANISMS OF CARDIOVASCULAR CALCIFICATION

Symposium

Chairperson(s): A.C. Newby (Bristol, GB); J. Waltenberger (Münster, DE)

- 08:30 **Molecular mechanisms of vascular calcification - the role of vascular smooth muscle cells.** 5190
 – C.M. Shanahan (London, GB)
- 08:52 **Inhibitors of vascular calcification - what have we learnt from animal models?** 5191
 – R. Westenfeld (Düsseldorf, DE)
- 09:15 **Cardiovascular calcification and long-term prognosis - can we detect the vulnerable patient?** 5192
 – J.J. Bax (Leiden, NL)
- 09:37 **Strategies for prevention and regression of vascular calcification - new treatment options?** 5193
 – A. Canfield (Manchester, GB)

08:30–10:00 | Tripoli - Village 1



NOVEL MECHANISMS AND IMAGING TOOLS IN ATHEROSCLEROSIS

Abstract Session

Chairperson(s): V. Adams (Leipzig, DE); S. Novo (Palermo, IT)

- 08:30 **Impaired neointima formation in mice lacking the coronary artery disease risk gene ADAMTS-7 after cessation of blood flow.** 5194
 – T. Kessler, Z. Aherrahrou, K. Schmidt, C. De Wit, H. Schunkert, J. Erdmann (Lübeck, DE)
- 08:45 **Adventitial inflammation is associated with thin-cap atheromas and expression of matrix-degrading enzymes and occurs in coronary regions exposed to low endothelial shear stress.** 5195
 – A.P. Antoniadis, M.I. Papafaklis, Y.S. Chatzizisis, G.K. Sukhova, A.B. Baker, A.U. Coskun, S. Takahashi, E.R. Edelman, P.H. Stone, C.L. Feldman (Boston, Austin and Cambridge, US)
- 09:00 **In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in mice.** 5196
 – C. Von Zur Muhlen, D. Von Elverfeldt, K. Wiens, M. Meissner, A. Charles, K. Peter, C. Bode, J.E. Fabre (Freiburg, DE; Illkirch, FR; Melbourne, AU)
- 09:15 **M1 and M2 macrophages expression profiles in human atherosclerosis and modulation by major cardiovascular risk factors.** 5197
 – C. Roma-Lavisse, C. Zawadzki, M. Tagzirt, C. Banfi, S. Haulon, G. Chinetti-Gbaguidi, B. Jude, S. Susen, E. Van Belle, A. Dupont (Lille, FR)
- 09:30 **Serum inflammatory biomarkers and plaque inflammation assessed by [18F]-fluorodeoxyglucose positron emission tomography in the dal-PLAQUE study: a post-hoc analysis by baseline features.** 5198
 – R. Duivenvoorden, V. Mani, M. Woodward, D. Kallend, G. Suchankova, V. Fuster, J.H.F. Rudd, A. Tawakol, M.E. Farkouh, Z.A. Fayad (New York and Boston, US; Sydney, AU; Basel, CH; Cambridge, GB; Toronto, CA)
- 09:45 **Galectin-3 binding protein/90K induces expression and shedding of the hemoglobin-haptoglobin scavenger receptor CD163 in human atherosclerotic plaque macrophages.** 5199
 – C.A. Gleissner, C.M. Helmes, C. Erbel, H.A. Katus (Heidelberg, DE)